Research programme: cardiovascular disorders therapies - CV Therapeutics/Pharmacopeia
Latest Information Update: 15 Jun 2007
At a glance
- Originator CV Therapeutics; Pharmacopeia
- Mechanism of Action Undefined mechanism
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
Highest Development Phases
- No development reported Cardiovascular disorders
Most Recent Events
- 27 Sep 2005 Preclinical trials in Cardiovascular disorders in USA (unspecified route)